Centessa Pharmaceuticals plc Insider Trading

CNTA

Last 12 months

Insiders sold $13.1M and bought nothing on the open market.

92% of the selling was scheduled in advance under 10b5-1 plans. Chief Legal Officer Iqbal J Hussain sold $1M on Feb 2, 25% of their stake, outside a plan. The last open-market buy by an executive or director was in May 2025.

Net open-market

−$13.1M

0 buys · 11 sales

Under a 10b5-1 plan

92%

of the value sold

Insiders who bought / sold

0 / 5

executives and directors

Last open-market buy

May 2025

May 16, 2025

Get an email when CNTA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jun 24	Medicxi Ventures Management (jersey) Ltd Large holder	SoldNo plan 6 parts	19,963,157	—	—	100%	Form 4
Jun 24	Index Ventures Life VI (jersey) L.p. Large holder	SoldNo plan 2 parts	9,961,789	—	—	100%	Form 4
Mar 26	Karen M. Anderson Chief People Officer	Sold10b5-1 plan	41,076	$30.12	$1.24M	40%	Form 4
Mar 26	Gregory M Weinhoff Chief Business Officer	Sold10b5-1 plan	23,998	$30.00	720K	27%	Form 4
Mar 16 – 17	Karen M. Anderson Chief People Officer	Sold10b5-1 plan 2 parts	74,811	$28.20 average	$2.11M	55%	Form 4
Mar 13	Karen M. Anderson Chief People Officer	Sold10b5-1 plan 2 parts	120,029	$26.25 average	$3.15M	66%	Form 4
Mar 13	Gregory M Weinhoff Chief Business Officer	Sold10b5-1 plan 2 parts	73,196	$26.33 average	$1.93M	53%	Form 4
Jan 30 – Feb 2	Iqbal J Hussain Chief Legal Officer	SoldNo plan 2 parts	39,961	$25.15 average	$1M	25%	Form 4
Dec 9, 2025	Mario Alberto Accardi President, Orexin Program	Sold10b5-1 plan 2 parts	10,000	$28.83 average	288K	5.3%	Form 4
Dec 8, 2025	Mario Alberto Accardi President, Orexin Program	Sold10b5-1 plan	10,000	$30.00	300K	5.0%	Form 4
Nov 17, 2025	Iqbal J Hussain General Counsel	Sold10b5-1 plan	6,000	$27.64	166K	5.4%	Form 4
Nov 17, 2025	Tia L Bush Chief Technology & Quality Ofc	Sold10b5-1 plan	40,000	$28.00	$1.12M	25%	Form 4
Nov 12, 2025	Tia L Bush Chief Technology & Quality Ofc	Sold10b5-1 plan	40,000	$26.00	$1.04M	25%	Form 4
Oct 27, 2025	Mario Alberto Accardi President, Orexin Program	Sold10b5-1 plan	8,000	$25.00	200K	4.0%	Form 4
Oct 15, 2025	Iqbal J Hussain General Counsel	Sold10b5-1 plan	6,000	$22.41	134K	5.1%	Form 4
Sep 24, 2025	Tia L Bush Chief Technology & Quality Ofc	Sold10b5-1 plan	35,000	$24.00	840K	22%	Form 4
Sep 16, 2025	Mario Alberto Accardi President, Orexin Program	Sold10b5-1 plan 2 parts	8,172	$21.39 average	175K	4.0%	Form 4
Sep 15, 2025	Iqbal J Hussain General Counsel	Sold10b5-1 plan	6,000	$21.85	131K	5.1%	Form 4
Sep 9, 2025 – Sep 10, 2025	Tia L Bush Chief Technology & Quality Ofc	Sold10b5-1 plan 2 parts	49,792	$21.00 average	$1.05M	29%	Form 4
Sep 9, 2025 – Sep 10, 2025	Iqbal J Hussain General Counsel	Sold10b5-1 plan 2 parts	40,000	$21.01 average	840K	27%	Form 4
Sep 9, 2025	Mario Alberto Accardi President, Orexin Program	Sold10b5-1 plan	7,000	$20.00	140K	3.3%	Form 4
Aug 15, 2025	Iqbal J Hussain General Counsel	Sold10b5-1 plan	6,000	$17.23	103K	5.1%	Form 4
Jul 29, 2025	Mario Alberto Accardi President, Orexin Program	Sold10b5-1 plan	8,322	$15.23	127K	3.8%	Form 4
Jul 25, 2025	Gregory M Weinhoff Chief Business Officer	Sold10b5-1 plan	10,000	$15.56	156K	7.6%	Form 4
Jul 21, 2025	Saurabh Saha Chief Executive Officer	Sold10b5-1 plan	55,000	$15.92	876K	18%	Form 4
Jul 15, 2025	Iqbal J Hussain General Counsel	Sold10b5-1 plan	6,000	$14.93	90K	5.1%	Form 4
Jun 25, 2025	Gregory M Weinhoff Chief Business Officer	Sold10b5-1 plan	10,000	$13.86	139K	7.6%	Form 4
Jun 24, 2025	Iqbal J Hussain General Counsel	Sold10b5-1 plan	12,000	$14.02	168K	9.8%	Form 4
Jun 24, 2025	Mario Alberto Accardi President, Orexin Program	Sold10b5-1 plan	15,000	$14.00	210K	6.5%	Form 4
Jun 20, 2025	Saurabh Saha Chief Executive Officer	Sold10b5-1 plan	55,000	$12.63	695K	18%	Form 4
May 27, 2025	Gregory M Weinhoff Chief Business Officer	Sold10b5-1 plan	10,000	$12.82	128K	7.6%	Form 4
May 20, 2025	Saurabh Saha Chief Executive Officer	Sold10b5-1 plan	55,000	$12.71	699K	18%	Form 4
May 15, 2025 – May 16, 2025	Arjun Goyal Director	Bought 2 parts	462,585	$12.68 average	$5.87M	New	Form 4
May 1, 2025	Iqbal J Hussain General Counsel	Sold10b5-1 plan	311	$14.00	4K	0.3%	Form 4
Apr 25, 2025 – Apr 28, 2025	Iqbal J Hussain General Counsel	Sold10b5-1 plan 2 parts	5,689	$14.00 average	80K	4.9%	Form 4
Apr 25, 2025	Gregory M Weinhoff Chief Business Officer	Sold10b5-1 plan	11,742	$13.61	160K	8.8%	Form 4
Apr 21, 2025 – Apr 22, 2025	Saurabh Saha Chief Executive Officer	Sold10b5-1 plan 2 parts	55,000	$12.39 average	682K	18%	Form 4
Mar 25, 2025	Gregory M Weinhoff Chief Business Officer	Sold10b5-1 plan	10,000	$16.34	163K	6.9%	Form 4
Mar 20, 2025	Saurabh Saha Chief Executive Officer	Sold10b5-1 plan	55,000	$16.69	918K	15%	Form 4
Mar 17, 2025	David M Chao Chief Administrative Officer	Sold10b5-1 plan 2 parts	7,000	$17.17 average	120K	3.0%	Form 4

Jun 24No plan
Medicxi Ventures Management (jersey) Ltd
Large holder · sold 19,963,157
—
100% of stake
Jun 24No plan
Index Ventures Life VI (jersey) L.p.
Large holder · sold 9,961,789
—
100% of stake
Mar 2610b5-1 plan
Karen M. Anderson
Chief People Officer · sold 41,076 at $30.12
$1.24M
40% of stake
Mar 2610b5-1 plan
Gregory M Weinhoff
Chief Business Officer · sold 23,998 at $30.00
720K
27% of stake
Mar 16 – 1710b5-1 plan
Karen M. Anderson
Chief People Officer · sold 74,811 at avg $28.20
$2.11M
55% of stake
Mar 1310b5-1 plan
Karen M. Anderson
Chief People Officer · sold 120,029 at avg $26.25
$3.15M
66% of stake
Mar 1310b5-1 plan
Gregory M Weinhoff
Chief Business Officer · sold 73,196 at avg $26.33
$1.93M
53% of stake
Jan 30 – Feb 2No plan
Iqbal J Hussain
Chief Legal Officer · sold 39,961 at avg $25.15
$1M
25% of stake
Dec 9, 202510b5-1 plan
Mario Alberto Accardi
President, Orexin Program · sold 10,000 at avg $28.83
288K
5.3% of stake
Dec 8, 202510b5-1 plan
Mario Alberto Accardi
President, Orexin Program · sold 10,000 at $30.00
300K
5.0% of stake
Nov 17, 202510b5-1 plan
Iqbal J Hussain
General Counsel · sold 6,000 at $27.64
166K
5.4% of stake
Nov 17, 202510b5-1 plan
Tia L Bush
Chief Technology & Quality Ofc · sold 40,000 at $28.00
$1.12M
25% of stake
Nov 12, 202510b5-1 plan
Tia L Bush
Chief Technology & Quality Ofc · sold 40,000 at $26.00
$1.04M
25% of stake
Oct 27, 202510b5-1 plan
Mario Alberto Accardi
President, Orexin Program · sold 8,000 at $25.00
200K
4.0% of stake
Oct 15, 202510b5-1 plan
Iqbal J Hussain
General Counsel · sold 6,000 at $22.41
134K
5.1% of stake
Sep 24, 202510b5-1 plan
Tia L Bush
Chief Technology & Quality Ofc · sold 35,000 at $24.00
840K
22% of stake
Sep 16, 202510b5-1 plan
Mario Alberto Accardi
President, Orexin Program · sold 8,172 at avg $21.39
175K
4.0% of stake
Sep 15, 202510b5-1 plan
Iqbal J Hussain
General Counsel · sold 6,000 at $21.85
131K
5.1% of stake
Sep 9, 2025 – Sep 10, 202510b5-1 plan
Tia L Bush
Chief Technology & Quality Ofc · sold 49,792 at avg $21.00
$1.05M
29% of stake
Sep 9, 2025 – Sep 10, 202510b5-1 plan
Iqbal J Hussain
General Counsel · sold 40,000 at avg $21.01
840K
27% of stake
Sep 9, 202510b5-1 plan
Mario Alberto Accardi
President, Orexin Program · sold 7,000 at $20.00
140K
3.3% of stake
Aug 15, 202510b5-1 plan
Iqbal J Hussain
General Counsel · sold 6,000 at $17.23
103K
5.1% of stake
Jul 29, 202510b5-1 plan
Mario Alberto Accardi
President, Orexin Program · sold 8,322 at $15.23
127K
3.8% of stake
Jul 25, 202510b5-1 plan
Gregory M Weinhoff
Chief Business Officer · sold 10,000 at $15.56
156K
7.6% of stake
Jul 21, 202510b5-1 plan
Saurabh Saha
Chief Executive Officer · sold 55,000 at $15.92
876K
18% of stake
Jul 15, 202510b5-1 plan
Iqbal J Hussain
General Counsel · sold 6,000 at $14.93
90K
5.1% of stake
Jun 25, 202510b5-1 plan
Gregory M Weinhoff
Chief Business Officer · sold 10,000 at $13.86
139K
7.6% of stake
Jun 24, 202510b5-1 plan
Iqbal J Hussain
General Counsel · sold 12,000 at $14.02
168K
9.8% of stake
Jun 24, 202510b5-1 plan
Mario Alberto Accardi
President, Orexin Program · sold 15,000 at $14.00
210K
6.5% of stake
Jun 20, 202510b5-1 plan
Saurabh Saha
Chief Executive Officer · sold 55,000 at $12.63
695K
18% of stake
May 27, 202510b5-1 plan
Gregory M Weinhoff
Chief Business Officer · sold 10,000 at $12.82
128K
7.6% of stake
May 20, 202510b5-1 plan
Saurabh Saha
Chief Executive Officer · sold 55,000 at $12.71
699K
18% of stake
May 15, 2025 – May 16, 2025
Arjun Goyal
Director · bought 462,585 at avg $12.68
$5.87M
New position
May 1, 202510b5-1 plan
Iqbal J Hussain
General Counsel · sold 311 at $14.00
4K
0.3% of stake
Apr 25, 2025 – Apr 28, 202510b5-1 plan
Iqbal J Hussain
General Counsel · sold 5,689 at avg $14.00
80K
4.9% of stake
Apr 25, 202510b5-1 plan
Gregory M Weinhoff
Chief Business Officer · sold 11,742 at $13.61
160K
8.8% of stake
Apr 21, 2025 – Apr 22, 202510b5-1 plan
Saurabh Saha
Chief Executive Officer · sold 55,000 at avg $12.39
682K
18% of stake
Mar 25, 202510b5-1 plan
Gregory M Weinhoff
Chief Business Officer · sold 10,000 at $16.34
163K
6.9% of stake
Mar 20, 202510b5-1 plan
Saurabh Saha
Chief Executive Officer · sold 55,000 at $16.69
918K
15% of stake
Mar 17, 202510b5-1 plan
David M Chao
Chief Administrative Officer · sold 7,000 at avg $17.17
120K
3.0% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CNTA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with CNTA

CompareIntrinsic value

IDYAIdeaya Biosciences Inc.

$32.36+3.29%40

SYRESpyre Therapeutics, Inc.

$99.24-0.03%10

PCRXPacira BioSciences Inc.

$36.40+0.03%58

HRMYHarmony Biosciences Holdings, Inc.

$34.42-7.04%82

LPCNLipocine Inc.

$1.44-1.37%40

VRTXVertex Pharmaceuticals Incorporated

$549.04+3.44%47

RYTMRhythm Pharmaceuticals Inc.

$110.68+28.04%40

DNTHDianthus Therapeutics Inc.

$85.81+3.76%10

Held by ETFs

CNTA is in 1 US ETF. The largest of them, with CNTA's weight in each:

Invesco Nasdaq Biotechnology ETFIBBQ0.38%of the fund

Spot a number that looks wrong? Check it in CNTA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CNTA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.